Back to Awarded Treatment Trials
Awarded Trial: 03T-408
Grant ID
03T-408
Illness
Bipolar Disorder
Primary Drug/Intervention
Valnoctamide
Primary Dosage
1200 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Agam
Sample Size
80
Duration of Study Period for Each Subject
5 weeks
Outcome Measurements
BPRS, YMS, CGI
Results
Valnoctamide, related to valproic acid, or a placebo were given to 41 patients with bipolar disorder to ascertain whether it was effective as a mood stabilizer. The dose was 1200 mg/d for 5 weeks. On measures of the BPRS, YMS, and CGI, valnoctamide was significantly more effective than placebo. This is being followed up, since valnoctamide is thought to be less teratogenic than valproic acid and thus may be useful for women with bipolar disorder who are pregnant or at risk for becoming pregnant.
Publication
N/A
Link
N/A
PI Name
Galila Agam
Degree
PhD
Center
Ben Gurion University
Institution
Ben Gurion University of the Negev
Address
P.O. Box 653
City or Town
Beer-Sheva
State or Province
N/A
Zip or Postal Code
84105
Country
Israel
Email Address
resco@bgumail.bgu.ac.il